BR112013033008A2 - "formulação farmacêutica líquida compreendendo nitisinona, seu uso e uso de nitinisona" - Google Patents
"formulação farmacêutica líquida compreendendo nitisinona, seu uso e uso de nitinisona"Info
- Publication number
- BR112013033008A2 BR112013033008A2 BR112013033008A BR112013033008A BR112013033008A2 BR 112013033008 A2 BR112013033008 A2 BR 112013033008A2 BR 112013033008 A BR112013033008 A BR 112013033008A BR 112013033008 A BR112013033008 A BR 112013033008A BR 112013033008 A2 BR112013033008 A2 BR 112013033008A2
- Authority
- BR
- Brazil
- Prior art keywords
- nitisinone
- liquid pharmaceutical
- pharmaceutical formulation
- nitinisone
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
resumo patente de invenção: "composição farmacêutica líquida compreendendo nitisinona". a presente invenção refere-se a uma formulação farmacêutica líquida adequada para administração oral, compreendendo uma suspensão de uma quantidade eficaz de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclo-hexanodiona (nitisinona) micronizada; e tampão de ácido cítrico apresentando um ph no intervalo de 2,5 a 3,5. a formulação é útil no tratamento de distúrbios e doenças nos quais é desejável a inibição de 4-hidroxifenilpiruvato dioxigenase (hppd), por exemplo, em tirosinemia hereditária tipo i.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1150585 | 2011-06-23 | ||
| SE1150585-6 | 2011-06-23 | ||
| PCT/SE2012/050681 WO2012177214A1 (en) | 2011-06-23 | 2012-06-20 | Liquid pharmaceutical composition comprising nitisinone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112013033008A2 true BR112013033008A2 (pt) | 2017-01-31 |
| BR112013033008A8 BR112013033008A8 (pt) | 2018-03-06 |
| BR112013033008B1 BR112013033008B1 (pt) | 2021-05-18 |
Family
ID=47422827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013033008-2A BR112013033008B1 (pt) | 2011-06-23 | 2012-06-20 | formulação farmacêutica líquida compreendendo nitisinona |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9301932B2 (pt) |
| EP (1) | EP2723320B1 (pt) |
| JP (1) | JP6038132B2 (pt) |
| CN (1) | CN103747781B (pt) |
| AU (1) | AU2012273515B2 (pt) |
| BR (1) | BR112013033008B1 (pt) |
| CA (1) | CA2838039C (pt) |
| CL (1) | CL2013003630A1 (pt) |
| CY (1) | CY1117273T1 (pt) |
| DK (1) | DK2723320T3 (pt) |
| ES (1) | ES2566787T3 (pt) |
| HR (1) | HRP20160286T1 (pt) |
| HU (1) | HUE027304T2 (pt) |
| IL (1) | IL229677A (pt) |
| MX (1) | MX2013014567A (pt) |
| PL (1) | PL2723320T3 (pt) |
| RS (1) | RS54632B1 (pt) |
| RU (1) | RU2605301C2 (pt) |
| SI (1) | SI2723320T1 (pt) |
| SM (1) | SMT201600097B (pt) |
| UA (1) | UA110979C2 (pt) |
| WO (1) | WO2012177214A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2723320T3 (pl) * | 2011-06-23 | 2016-06-30 | Swedish Orphan Biovitrum Int Ab | Ciekła kompozycja farmaceutyczna zawierająca nityzynon |
| WO2013181292A1 (en) * | 2012-05-29 | 2013-12-05 | Biotie Therapies, Inc. | Nitisinone formulations |
| CA2947062A1 (en) | 2014-04-30 | 2015-11-05 | Swedish Orphan Biovitrum International Ab | Nitisinone dosing regimens for the treatment of alkaptonuria |
| CN104623428A (zh) * | 2015-03-13 | 2015-05-20 | 庄彩梅 | 一种缓解遗传性酪氨酸血症的中药制剂及其制备方法 |
| ITUB20160650A1 (it) | 2016-02-11 | 2017-08-11 | Dipharma S A | Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione |
| ITUB20160972A1 (it) * | 2016-02-23 | 2017-08-23 | Univ Degli Studi Di Siena | Trattamento dell’alkaptonuria e della tirosinemia di tipo 1 |
| CN110464716A (zh) * | 2019-09-03 | 2019-11-19 | 黄嘉若 | 一种尼替西农在制备治疗肺癌药物中的用途 |
| CN112107548A (zh) * | 2020-10-30 | 2020-12-22 | 兆科药业（广州）有限公司 | 一种含有尼替西农的药物组合物及其制备方法 |
| CN114831974A (zh) * | 2022-06-23 | 2022-08-02 | 徐州医科大学 | 尼替西农在制备预防和治疗内毒素性休克疾病药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006158A (en) | 1984-12-20 | 1991-04-09 | Ici Americas Inc. | Certain 2-(2-substituted benzoyl)-1,3-cyclohexanediones |
| US4695673A (en) | 1985-11-20 | 1987-09-22 | Stauffer Chemical Company | Process for the production of acylated 1,3-dicarbonyl compounds |
| AU672361B2 (en) * | 1991-06-24 | 1996-10-03 | Swedish Orphan Biovitrum International Ab | Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of tyrosinaemia and pharmaceutical compositions |
| US5668089A (en) | 1996-04-08 | 1997-09-16 | Zeneca Limited | Selective corn herbicide |
| WO2004005321A2 (en) | 2002-07-03 | 2004-01-15 | The Rockefeller University | Methods of inhibiting 4-hydroxyphenylpyruvate dioxygenase in a living system |
| GB0405760D0 (en) | 2004-03-15 | 2004-04-21 | Syngenta Participations Ag | Agrochemical formulation |
| GB0414895D0 (en) | 2004-07-02 | 2004-08-04 | Syngenta Ltd | Herbicidal formulation |
| GB0504103D0 (en) * | 2005-02-28 | 2005-04-06 | Syngenta Ltd | Novel method |
| CA2659424A1 (en) | 2006-08-18 | 2008-02-21 | Syngenta Limited | Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| EP2356130A4 (en) * | 2008-11-06 | 2012-05-02 | Biotie Therapies Ag | TREATMENT OF NON-REST LEG SYNDROME AND OTHER SLEEP DISORDERS |
| US8354451B2 (en) * | 2009-03-09 | 2013-01-15 | The Uwm Research Foundation, Inc. | Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase |
| PL2723320T3 (pl) * | 2011-06-23 | 2016-06-30 | Swedish Orphan Biovitrum Int Ab | Ciekła kompozycja farmaceutyczna zawierająca nityzynon |
| WO2013181292A1 (en) * | 2012-05-29 | 2013-12-05 | Biotie Therapies, Inc. | Nitisinone formulations |
-
2012
- 2012-06-20 PL PL12802262T patent/PL2723320T3/pl unknown
- 2012-06-20 MX MX2013014567A patent/MX2013014567A/es active IP Right Grant
- 2012-06-20 HU HUE12802262A patent/HUE027304T2/en unknown
- 2012-06-20 WO PCT/SE2012/050681 patent/WO2012177214A1/en active Application Filing
- 2012-06-20 CN CN201280030236.9A patent/CN103747781B/zh active Active
- 2012-06-20 EP EP12802262.1A patent/EP2723320B1/en active Active
- 2012-06-20 DK DK12802262.1T patent/DK2723320T3/en active
- 2012-06-20 BR BR112013033008-2A patent/BR112013033008B1/pt active IP Right Grant
- 2012-06-20 AU AU2012273515A patent/AU2012273515B2/en active Active
- 2012-06-20 CA CA2838039A patent/CA2838039C/en active Active
- 2012-06-20 RU RU2014101990/15A patent/RU2605301C2/ru active
- 2012-06-20 US US14/129,090 patent/US9301932B2/en active Active
- 2012-06-20 JP JP2014516952A patent/JP6038132B2/ja active Active
- 2012-06-20 RS RS20160163A patent/RS54632B1/en unknown
- 2012-06-20 SI SI201230504A patent/SI2723320T1/sl unknown
- 2012-06-20 ES ES12802262.1T patent/ES2566787T3/es active Active
- 2012-06-20 UA UAA201400625A patent/UA110979C2/uk unknown
-
2013
- 2013-11-28 IL IL229677A patent/IL229677A/en active IP Right Grant
- 2013-12-18 CL CL2013003630A patent/CL2013003630A1/es unknown
-
2015
- 2015-03-05 US US14/639,929 patent/US20150174081A1/en not_active Abandoned
-
2016
- 2016-03-03 CY CY20161100186T patent/CY1117273T1/el unknown
- 2016-03-21 HR HRP20160286TT patent/HRP20160286T1/hr unknown
- 2016-04-05 SM SM201600097T patent/SMT201600097B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013033008A2 (pt) | "formulação farmacêutica líquida compreendendo nitisinona, seu uso e uso de nitinisona" | |
| BR112013022495A2 (pt) | formulação farmacêutica aquosa de tapentadol para administração oral | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
| BR112014016085A2 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112014004963A2 (pt) | sal de colina do composto anti-inflamatório ciclobutanodiona substituído | |
| BR112015003796A2 (pt) | composição ansiolítica, formulação e método de uso | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112014010223B8 (pt) | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica | |
| BR112014015845A2 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
| BR112013008005A2 (pt) | composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo | |
| BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
| BRPI0918602B8 (pt) | inibidores da atividade de ssao, seu uso, e formulação farmacêutica | |
| BR112015017331A2 (pt) | compostos químicos | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| BR112014027884A2 (pt) | combinações farmacêuticas para tratamento de distúrbios metabólicos | |
| BR102013003570A8 (pt) | Composições de plasma rico em plaquetas | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| BR112015019264A8 (pt) | cápsulas para o tratamento de helicobacter pylori e seu uso". | |
| BR112019002513A2 (pt) | uso e dosagem de agentes terapêuticos para endometriose | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| BR112014004732A2 (pt) | composto benzotiazolona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/06/2012, OBSERVADAS AS CONDICOES LEGAIS. |